Online Grant Application and Management Portals
Lilly provides grants and charitable contributions for healthcare professional education, patient advocacy and consumer education programs in a variety of therapeutic areas through the Lilly Grant Office.
Additionally, Lilly has entered into partnerships and alliances with other pharmaceutical companies and established grant offices to support continuing medical education for healthcare professionals in specific therapeutic areas.
The application process for all of our grant offices is online. Detailed information about how to register and apply, including documentation requirements, review process, and decision notification, is available in each of the online grant application and management portals.
Important Note: Any organization found to be listed on the Office of Inspector General's List of Excluded Individual/Entities (OIG LEIE) or the General Services Administration Excluded Parties List System (GSA EPLS) will not be allowed to register or submit grant applications. Requesting organizations will be required to accept all terms and conditions of the grant application process.
Eli Lilly and Company is committed to improving patient care and providing valuable information to the medical and broader healthcare community. Lilly accepts requests for healthcare professional education, patient advocacy and consumer education programs. Our areas of focus include: cardiovascular, chronic pain, endocrine, autoimmune diseases, neuroscience, oncology, men’s health, and musculoskeletal.
Partners in Cardiology
Daiichi Sankyo – Lilly Grant Office (https://portal.dslgrantoffice.com)
The Daiichi Sankyo, Inc (Daiichi Sankyo) and Eli Lilly and Company (Lilly) alliance brings together two leaders in healthcare to develop and deliver innovative medicines that contribute to longer and healthier lives. As part of this alliance, we are committed to supporting projects that promote excellence in patient care and provide valuable information to the medical community in the therapeutic area of cardiology.
Partners in Diabetes
Boehringer Ingelheim – Lilly Grant Office ()
On January 11, 2011 Boehringer Ingelheim Pharmaceutical Inc. (BIPI) and Lilly announced a global agreement to jointly develop a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.